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Abstract 
Myeloid cells crosstalk with T cells and prevent anti-tumor T cell responses in a STAT3-
dependent manner. We investigated the role of STAT3 in myeloid stromal cells of murine 
autochthonous colorectal cancers (CRCs). Conditional ablation of STAT3 in myeloid cells 
(STAT3¨M) strongly suppressed formation of Azoxymethane/Dextransulfate (AOM/DSS-
induced CRCs. Tumors that succeeded to develop in STAT3¨M mice displayed enhanced 
stromalization with altered composition of stromal immune cells. Transplantation of MC38 
tumor cells into STAT3¨M host mice indicated that growth of CRCs was preferentially 
controlled by aberrant T cell activities. Gene expression profiling of autochthonous STAT3¨M 
CRCs demonstrated that aberrant T cell activation was maintained in the tumor stroma and 
not suppressed by tumor derived factors. Moreover, STAT3¨M CRCs displayed profound 
activation of STAT3, Myc and TGFß signaling in tumor cells whereas NFțB/p65 signaling 
was compromised. These tumor cell-autonomous molecular changes might contribute to 
editing and immune escape of CRCs. Therefore, targeting these pathways could improve the 
efficacy of immune therapies and prevent relapse of escaped cancers.   
Introduction 
Colorectal cancer (CRC) represents the third most common form of cancer in humans 
worldwide. Major mutations leading to CRC formation have been identified in genes for 
adenomatous polyposis coli (Apc),  K-ras, components of the TGFß signalling pathway 
(Smad4 or TGFßRII) and p531. CRCs develop frequently in the context of inflammatory 
bowel disease demonstrating a tumor-promoting role of inflammation2. Moreover, a robust 
infiltration of T cells, B cells, neutrophils, dentritic cells (DCs), natural killer cells (NKs), tumor-
associated macrophages (TAMs) and myeloid derived suppressor cells (MDSCs) is observed 
in the CRC tumor stroma2. Stromal immune cells support growth of CRC via production of 
cytokines that activate the oncogenic transcription factors NFțB and STAT33. Moreover, the 
stroma contains immune cells with anti-tumor activities which force tumors to develop 
mechanisms of escape and immune suppression4. One paradigm is the ability of tumors to 
modulate polarization of TAMs. Bacterial LPS and the Th1 cytokine IFNȖ polarize 
macrophages towards the classical M1 phenotype which is responsible for innate immune 
attack of infectious pathogens but also neoplastic cells. Alternative activation by Th2 
cytokines IL4 and IL13 polarizes macrophages towards the M2 phenotype which is 
characterized by low expression of M1 markers (IL12, iNos) but high expression of M2 
markers (IL10, VEGF, matrix metalloproteases, IL1decoyR, Arginase-1, CCL17, CCL22)5, 6. 
M2 macrophages have reduced anti-tumorigenic activities but are considered to promote 
angiogenesis and tumor progression5, 6. Repolarization of M2 macrophages towards the M1 
phenotype represents a promising option for stromal anti-tumor therapies which was recently 
demonstrated in a mouse model for glioblastoma7. Another layer of complexity was recently 
discovered in breast tumors where an additional TAM population, distinguishably from M1 or 
M2 polarized macrophages, was identified8.  
STAT3 phosphorylation at tyrosine residue 705 (pY-STAT3) via Janus kinases (JAKs) is 
induced by pro- and anti-inflammatory cytokines such as IL6, IL10, IL11, IL21 and IL239. The 
oncogenic role of STAT3 in CRC tumor cells has been demonstrated in several studies10-13. 
However, STAT3 seems to have a tumor-suppressive role in advanced CRCs because 
ApcMin mice lacking STAT3 in tumor cells developed aggressive intestinal carcinomas that 
were not observed in ApcMin control animals14-16. STAT3 promotes CRC formation via 
regulation of genes implicated in cell survival and cell proliferation17, 18 and modulates nuclear 
localization of ß-Catenin by post-transcriptional mechanisms16, 19. In addition, STAT3 
activation represents an important immune escape mechanism as cancer cells exploit 
STAT3-induced expression of VEGF and IL10 to blunt maturation of stromal DCs. An 
immune suppressive action is further given by the STAT3 dependent repression of pro-
inflammatory cytokines and chemokines including IFNȖ, TNFĮ, IL6 and IP1020, 21.  
Apart from tumor-cell specific functions, STAT3 is considered to promote tumor formation 
when being activated in stromal cells of CRCs16, 17, 22. STAT3 activation is the result of 
cytokines produced by both, stromal and tumor cells. Thereby a reciprocal feedback loop 
between tumor cells and stromal cells is established that maintains STAT3 activation in both 
cellular compartments21. Tumor transplantation experiments into host mice lacking STAT3 in 
the hematopoietic system demonstrated that STAT3 activation in immune cells prevents anti-
tumorigenic activities of DCs, Th1 cells, NKs and neutrophils23. This led to the concept of 
inhibiting stromal/hematopoietic STAT3 as potential strategy for cancer immunotherapy24. 
Myeloid STAT3 is considered of particular importance for the modulation of Th1-like anti-
tumor responses25. STAT3 directly regulates the expression of the pro-tumorigenic cytokine 
IL23 whereas production of the Th1 cytokine IL12 by dentritic cells is suppressed via an 
indirect NFțB-dependent mechanism26. Consequently, inhibition of STAT3 in myeloid cells 
and B cells using CpG-STAT3 siRNA enhanced cytotoxic T cell (CTL)-mediated responses in 
a melanoma transplantation model27.  
Here we demonstrate that ablation of myeloid STAT3 significantly interfered with 
development of autochthonous AOM/DSS-induced colorectal tumors in mice. This effect was 
mediated by an enhanced anti-tumor T cell response. Weighted gene correlation network 
analysis of STAT3¨M tumor and stroma tissue uncovered sustained T cell-mediated immune 
surveillance in escaped tumors which was accompanied by deregulation of several 
inflammatory signaling pathways in tumors cells. The latter might be part of a signaling 
network that contributes to immune editing which implicates that targeting of these pathways 
could synergistically improve the efficacy of immune therapies.  
  
Results 
 
Myeloid STAT3 promotes formation of colorectal tumors 
We investigated the role of STAT3 in the myeloid stromal cells of autochthonous colorectal 
tumors developing under inflammatory conditions. For this purpose, we used mice with 
conditional inactivation of STAT3 in myeloid cells (STAT3¨M = LysMCre/Cre STAT3flox/flox) and 
corresponding controls (STAT3wt = LysMCre/Cre STAT3+/+). Successful deletion of STAT3 in 
myeloid cells was confirmed by Western blot analysis in granulocyte-macrophage precursors 
differentiated from bone marrow cells in vitro and FACS-sorted peritoneal macrophages 
(Supplementary Figure 1a) as well as by qPCR analysis of FACS-sorted splenic 
macrophages (Supplementary Figure 1b). Histopathological analysis and IHC-staining 
revealed no major changes of cell differentiation or proliferation in colon and small intestine 
of STAT3¨M mice except for a slight reduction of enteroendocrine cell numbers 
(Supplementary Figure 2a). Deletion of STAT3 in myeloid cells provokes Th1 differentiation 
and development of colitis28, 29. However, we failed to detect severe colitis in STAT3¨M mice 
using histopathology and IHC-staining for macrophages and T cells in the C57BL/6 genetic 
background used (Supplementary Figure 2b). However, flow cytometric analysis of colonic 
lamina propria immune cells from STAT3¨M mice after short term challenge with DSS 
uncovered a consistently increased mean fluorescence intensity of the activating protein 
CD69 on CD4+ T cells (Supplementary Figure 3) which is associated with Th1 
differentiation30.  
To investigate the impact of myeloid STAT3 in autochthonous tumors, we induced colorectal 
cancer in STAT3wt and STAT3¨M mice using the Azoxymethan/Dextransulfate (AOM/DSS) 
protocol (Figure 1a). Tumor formation was significantly impaired in STAT3¨M mice (Figure 
1b). The numbers of tumor nodules detectable was reduced irrespective of the gender 
whereas the mean tumor area was only reduced in female STAT3¨M mice (Figure 1b). For all 
further analysis, CRCs from male STAT3¨M mice were investigated. Tumor parameters such 
as cell proliferation and cell survival were not significantly altered in STAT3¨M CRCs (Figure 
1c). However, we found increased numbers of blood vessels in the tumor stroma (Figure 1d). 
These data indicate that STAT3 in myeloid cells promotes formation of AOM/DSS-induced 
CRCs by mechanisms distinct from proliferation or apoptosis.  
 
Myeloid STAT3 regulates stromal composition of CRCs 
Tumor progression depends on the reciprocal crosstalk between tumor and stroma cells. 
Remarkably, histopathologic and immunohistochemical examination revealed an increased 
stromalization of STAT3¨M CRCs when compared with STAT3wt CRCs (Figure 2a). Although 
increased stromalization is frequently associated with tumor progression and enhanced 
invasiveness, no significant alteration in the percentages of low grade tumors, high grade 
tumors and carcinomas was observed in STAT3¨M mice (Figure 2d).  
Within the tumor stroma the immune cell composition differed in STAT3¨M CRCs. The 
percentages of Gr1+ granulocytes and FoxP3+ regulatory T cells were reduced whereas 
neutrophilic esterase+ neutrophils, RORȖt+ Th17 cells and toluidine blue-stained mast cells 
were almost absent. In contrast, CD45R+ B cells were found at higher numbers (Figure 2b; 
Supplementary Figure 4). Interestingly, NKp46+ NK cells accumulated preferentially at the 
margin of STAT3¨M CRCs (Supplementary Figure 4h). Consistent with a role of STAT3 in 
polarization of macrophages we found a reduction of cells expressing the M2 protein 
Arginase-1 paralleled by an increase in the number of M1 expressing iNOS-positive cells 
(Figure 2c). The percentages of stromal cells expressing NK proteins NKG2A and NKG2D as 
well as cells expressing the cytotoxic factor Granzyme B (cytotoxic T cells and granulocytes) 
was not significantly altered in the stroma of STAT3¨M CRCs (Figure 2c). These data indicate 
that STAT3 in myeloid cells determines the cellular composition of the CRC tumor stroma.  
 
Myeloid STAT3 is not required for NK cell-mediated immune surveillance of CRCs 
Loss of STAT3 in myeloid cells leads to an aberrant activation of NK and T cells23, 31.  Thus, 
we studied whether reduced tumorigenesis is due to an improved immune surveillance 
exerted by NK and T cells. NK cell-dependent cytotoxicity was assessed in vitro using 
spleen-derived NK cells and CFSE-stained Yac-1 target cells. No significant differences in 
killing efficacies of NK cells isolated from STAT3wt or STAT3¨M mice were detected (Figure 
3a). Similarly, numbers of CD3- NK1.1+ DX5+ NKp46+ NK cells in the spleen and the 
expression of NK cell maturation markers (CD27, KLRG-1) were unchanged (Supplementary 
Figure 5a) as were the percentages of NKG2D+, NKG2A/C/E+, DNAM-1+ and Ly49C/I+ NK 
cells (Supplementary Figure 5b). We detected only one consistent change: the number of NK 
cells expressing the activating receptor Ly49D, which recognizes MHC class I alloantigens, 
was reduced in STAT3¨M mice (Figure 3b) whereas the mean fluorescence intensity of the 
activating receptor NKG2D (but not NKGD2A/C/E) was increased (Figure 3c). As NKG2D is 
an important receptor for the recognition of stress-induced ligands on tumors, we performed 
transplantation experiments with isogenic C57BL/6-derived p185 leukemia cells that are 
eradicated by NK cell-mediated mechanisms. Although p185-derived tumors were slightly 
smaller in STAT3¨M host animals, indicative for an improved NK cell-mediated tumor 
surveillance, the differences did not reach statistical significance (Figure 3d).  
We next investigated the impact of NK cell-mediated immune surveillance on formation of 
autochthonous CRCs. For that purpose, we treated STAT5wt and STAT5¨NK mice with 
AOM/DSS. STAT5¨NK mice represent a model for genetic ablation of NK cell functions32. No 
significant increase in AOM/DSS-induced tumor formation was observed in STAT5¨NK mice 
despite of a substantial reduction of NKp46+ cell numbers in the gut (Figure 3e). These data 
suggest that NK cell-mediated killing activities do not significantly contribute to immune 
surveillance of AOM/DSS-induced CRCs.  
 
Myeloid STAT3 is required for T cell-mediated immune surveillance of CRCs 
Apart from NK cells, cytotoxic T cells (CTLs) and helper T cell functions are key determinants 
for tumor immune surveillance. In particular for human CRCs, it has been demonstrated that 
stromal T cell infiltration correlates with better prognosis33. Therefore, we performed in vivo 
cytotoxicity assays in STAT3wt and STAT3¨M mice. m-TRP2181-188-immunized STAT3¨M mice 
displayed a slight but significantly enhanced killing activity of m-TRP2181-188-pulsed CFSE-
labeled splenocytes in vivo (Figure 4a) indicating enhanced cytotoxic T cell activity in 
STAT3¨M mice even in the absence of tumors. To address whether the enhanced T cell-
dependent cytotoxicity extends to CRCs, we transplanted isogenic colorectal MC38 cancer 
cells into STAT3wt and STAT3¨M hosts. Remarkably, tumor growth was significantly impaired 
in STAT3¨M host animals (Figure 4b). Reduced tumor growth was accompanied by higher 
numbers of CD4+ T cells but only slightly increased numbers of CD8+ cytotoxic T 
lymphocytes in tumor lysates (Figure 4c). However, the percentages of CD4+ or CD8+ T cells 
co-expressing the activation marker CD69 were similar in STAT3wt and STAT3¨M hosts (data 
not shown). The number of GR1hi CD11b+ MDSCs was also elevated in tumors of STAT3¨M 
host mice whereas GR1lo CD11b+ CD11clo tumor-associated macrophages were reduced 
(Figure 4c). MDSCs can provide a costimulatory signal for T cell activation and survival 
through expression of CD80, a ligand for CD28. Indeed, higher numbers of GR1hi CD11b+ 
CD80+ MDSCs were present in MC38 tumors of STAT3¨M hosts (data not shown). No 
changes in NK cell infiltration and only a slightly increased expression of NKG2D on 
infiltrating NK cells were observed (Figure 4c and data not shown). Moreover, RaeI and 
MHCI protein expression levels were similar on MC38 tumor cells (data not shown). These 
data indicate that growth of colorectal cancer cells is preferentially limited by T cell-mediated 
antitumor immunity.   
 
CRCs of STAT3¨M mice escape T cell-mediated killing 
In order to molecularly characterize immune-mediated mechanisms in AOM/DSS-induced 
CRCs, microarray gene expression profiling was performed with RNA samples from 
microdissected tumor and stroma tissue of paraffin-embeded and formalin-fixed tissues. 
Microarray data of the stroma tissues were subjected to weighted gene correlation network 
analysis (WGCNA). Modules of high correlation for genes implicated in immune responses, 
cytokine production and angiogenesis were identified (Supplementary Figure 6). The latter 
correlated with the increased density of blood vessels observed in the stroma of STAT3ǻM 
tumors (Figure 1d). However, network plots revealed no clear deregulation of individual 
angiogenesis pathways suggesting that blood vessel formation is promoted by a complex 
molecular mechanism (Supplementary Figure 7). In contrast, network plots for GO terms in 
immune modules revealed a clear result with massive upregulation of corresponding genes 
in the stroma of STAT3ǻM tumors (Figure 5). A “T cell activation” network plot demonstrated a 
strong correlation between dock2/ptpn6/thy1 and dock2/CD48/tnfrsf4 expression. Moreover, 
upregulation of cytokine/chemokine receptors, MHC class II molecules and complement 
factors was identified in “T cell activation”, “adaptive immune response“, “innate immune 
response“ and “positive regulation of immune response“ network plots (Figure 5a). 
Corresponding network plots for response and production of cytokines demonstrated 
correlations between Irg1/IL-1ß/Cxcl10 and Irg1/IL-1ß/Hilpda expression (Figure 5b). These 
results suggest a strong enhancement of immune responses that are particularly related to T 
cell activation. Consistently, genes belonging to the Immunologic Constant of Rejection (ICR) 
signature34 and genes indicative for T cell activation were upregulated in the stroma of 
STAT3ǻM CRCs (Supplementary Figure 9a, b). Interestingly, expression of PD-L1 and PD-L2, 
two ligands that antagonize T cell activities, were also upregulated (Supplementary Figure 
9b) which might represent an adaptive response to limit T cell activation. These data suggest 
that AOM/DSS-induced CRCs in STAT3¨M mice are under control of T cell-mediated immune 
surveillance which leads to reduced tumor numbers.  
 
Cell-autonomous changes of putative immunoediting pathways in STAT3¨M CRCs 
Remarkably, the enhanced stromal T cell activation had no impact on the size of AOM/DSS-
induced STAT3¨M tumors at least in male mice (Figure 1b). This indicates that CRCs develop 
strategies to escape the strong immunogenic environment in STAT3¨M mice. Therefore, we 
investigated microarray expression data, obtained with microdissected tumor cell tissue, for 
molecular processes indicative for immunoediting. RNA expression of immunosuppressive 
tumor-derived factors (Supplementary Figure 9c) and NKG2D stress-induced ligands 
(Supplementary Figure 9d) was not significantly altered in STAT3¨M CRCs. Protein 
expression of the NKGD2 ligand H60, as assessed by IHC, was not detectable in STAT3wt 
and STAT3¨M CRCs (data not shown). Moreover, protein expression of RaeI was not 
significantly reduced in cancer cells of STAT3¨M mice (data not shown) excluding selective 
immunoediting for RaeIlow CRCs in order to escape NK cell killing. Interestingly, STAT3¨M 
CRCs contained increased numbers of stromal CD45R+ B cells (Figure 2b) and complement 
factors were upregulated (Figure 5, “adaptive immune response”). However, expression of 
mCRPs, which protect tumor cells from complement attack, was not differentially regulated in 
STAT3wt and STAT3¨M CRCs (Supplementary Figure 9e). These data indicate that no 
selective immunoediting for mCRPhigh CRCs in order to escape complement-mediated tumor 
killing has occurred.  
Little is known about signaling pathways in tumor cells that promote immune escape but a 
positive role has been attributed to STAT3. Therefore, we used the Molecular Signature 
Database of the Broad Institute for identification of differentially regulated signaling 
pathways. Overlap analysis of genes upregulated in STAT3¨M tumor cells (>2-fold) with 
curated gene sets identified “fevr_ctnnb1_targets_up” and “zheng_IL22_signaling_up” as 
most significant candidates. These gene sets represents genes that are upregulated in 
intestinal crypt cells upon deletion of ß-catenin35 and genes upregulated in colonic tissue 
after treatment with IL22 (a potent inducer of STAT3 activity)36, respectively. This indicated 
that Wnt signaling was compromised and STAT3 signaling was aberrantly activated in 
STAT3¨M tumor cells. However, IHC analysis revealed no significant reduction of ß-Catenin-
positive tumor cells in STAT3¨M mice (Supplementary Figure 8). Remarkably, levels of 
STAT3 and activated STAT3 (pY-STAT3) were significantly elevated in STAT3¨M tumor cells 
(Figure 6a).  
Overlap analysis of genes downregulated in STAT3¨M tumor cells (>2-fold) identified 
“karlsson_tgfß1_targets_dn“, “phong_tnf_response_via_p38_partial” and again several gene 
sets implicated in Wnt signaling with “sansom_wnt_pathway_require_myc“ as most 
significant candidate. The latter is derived from a study demonstrating that Myc regulates 
most Wnt target genes in the small intestine37. This suggests that we identified Wnt signaling 
gene sets in the absence of ß-Catenin deregulation because of aberrant Myc expression. 
Consistent with this hypothesis, Myc expression was increased in STAT3¨M tumor cells 
(Figure 6b). The “karlsson_tgfß1_targets_dn“ and “phong_tnf_response_via_p38_partial” 
gene sets represent genes downregulated by TGFß1 in MEFs38 and genes that are activated 
by TNFĮ in Calu-6 lung cancer cells39, respectively. This data indicated that TGFß signaling 
was aberrantly activated whereas NFțB signaling was compromised in STAT3¨M tumor cells. 
Consistently, levels of the p65 NFțB subunit were reduced in STAT3¨M tumor cells (Figure 
6c). Moreover, pSmad2 levels were increased in STAT3¨M tumor cells (Figure 6d) which 
correlated with increased numbers of TGFß-producing cells in the tumor stroma (Figure 6e). 
In summary, these data suggest that STAT3¨M CRCs have established a signaling network 
that contributes to tumor immune escape.  
  
Discussion 
Macrophages with disruption of STAT3 signaling have a constitutively activated phenotype 
and are capable of restoring the tumor responsiveness of tolerant T cells suggesting an 
important implication for cancer immunotherapy31. The consequences of hematopoietic 
STAT3 targeting on augmentation of anti-tumor immune responses have been 
comprehensively studied in tumor cell transplantation models20. In contrast, the applicability 
of STAT3-based immunotherapy on autochthonous tumors is not well defined. It is also 
unclear if and through which molecular mechanisms autochthonous tumors adapt to STAT3-
based immune surveillance. Targeting potential escape mechanisms might not only improve 
immunotherapy but also prevent tumor relapse. We describe for the first time that ablation of 
myeloid STAT3 interferes with development of autochthonous tumors in mice. The use of an 
autochthonous tumor model allowed us to investigate the cellular and molecular 
consequences of myeloid STAT3 ablation on stroma and tumor compartments. The data 
suggest that cross activation of anti-tumor T cell responses by STAT3-deficient myeloid cells 
cannot be efficiently suppressed by tumor-derived factors in colitis-associated CRCs. 
However, tumor cells seem to employ intrinsic molecular mechanisms to escape the strong 
immunogenic microenvironment in Stat3ǻM mice.  
Two types of inflammation have been described: “Bad inflammation” is characterized by the 
presence of Th2 cells, MDSCs, Tregs and M2 polarized macrophages and represents a 
tumor-promoting condition. “Good inflammation” is characterized by the presence of Th1 
cells, CTLs, DCs and M1 polarized macrophages which mount an anti-tumor immune 
attack40, 41. However, even “good inflammation” can promote cancer formation through the 
mutagenic action of reactive oxygen species (ROS), chronic tissue damage and 
regeneration2. Loss of STAT3 in hematopoietic cells including macrophages and DCs results 
in spontaneous gut inflammation but it is unclear if this condition promotes or prevents 
formation of colitis-associated CRCs29, 42, 43. Interestingly, we have not observed a severe 
spontaneous colitis phenotype in Stat3ǻM mice which was also reflected by a normal life span 
and fertility of Stat3ǻM mice. This might be due to the used C57/BL6 genetic background or 
an alternative composition of the intestinal microflora because enterocolitis is significantly 
improved in Stat3ǻM mice by ablation of TLR4 signaling28. Moreover, Stat3ǻM and Stat3wt mice 
responded similarly to DSS with respect to the activation status of intestinal inflammatory 
cells and colitis score indicating that aberrant immune responses did not occur in Stat3ǻM 
mice in the absence of tumors. This is consistent with the NK and T cell activation assays, 
performed without tumor challenge, and corroborated by published data23. Therefore, 
STAT3-deficient myeloid cells seem to selectively promote tumor immune surveillance 
without major effects on non-tumor related immune cell functions. Enhanced immune 
surveillance seems to rely on myeloid cross activation of T cell rather than NK cell activities 
as demonstrated by p185 and MC38 cell transplantation studies. Similarly, AOM/DSS-
induced Stat3ǻM CRCs might be primarily eradicated by T cell responses. This is consistent 
with the presence of stromal gene expression signatures in Stat3ǻM tumors that are indicative 
for T cell activation. NK cell activities seem to play a minor role in immune surveillance of 
AOM/DSS-induced CRCs because Stat3ǻM tumors displayed no stromal gene expression 
signature indicative for NK cell-mediated cytotoxicity and did not show downregulation of 
NKG2D stress-induced protein ligands. Moreover, CRC formation was not promoted in 
STAT5¨NK mice which display reduced NK cell activities32. However, the intestine also 
contains an autonomous NK cell compartment distinct from conventional NK cells that could 
exert anti-tumor activities44.  
A strong intratumoral CTL infiltration was observed in the majority of patients with early-stage 
CRCs whereas patients with a low cytotoxic response evolved to late-stage disease34. 
Moreover, it has been demonstrated that CD3+, CD8+ and CD45RO+ stromal T cell densities 
and their intratumoral locations (Immunoscore) represents a better prognostic marker than 
conventional TNM staging45. Additional determination of a core gene expression signature 
called ICR (Immunologic Constant of Rejection) including ifng, il12, tbx21, irf1, stat1, gzma, 
gzmb, prf1, cxcl9, cxcl10, ccl5, cx3cl1, ccl2, madcam1, icam1 and vcam1 genes can refine 
the accuracy of prognosis34. T cells were the most abundant stromal cell type in AOM/DSS-
induced CRCs although number and distribution of CD3+ and CD8+ cells was not different in 
Stat3ǻM and Stat3wt mice. Despite the unchanged Immunoscore, Stat3ǻM tumors displayed 
upregulation of several core ICR genes (irf1, stat1, cxcl9 and ccl5) indicating that these 
marker genes are predictive for good prognosis in mice and humans. Among these core 
genes is ccl5 which encodes for the chemokine RANTES. RANTES is produced by STAT3-
deficient myeloid cells and has been identified as a chemokine that prevents T cell anergy in 
tumor immune surveillance31. The ICR signature of Stat3ǻM tumors had, however, no impact 
on tumor grading. Similarly, Cox multivariate analysis demonstrated that the T and N stages 
of early-stage human CRCs did not significantly correlate with their Immunoscore albeit T 
and N stages of advanced CRCs did34.  
Remarkably, STAT3 in myeloid cells regulates the stromal composition of CRCs which might 
result in pleiotropic tumor-promoting or tumor-suppressive effects. The altered stromal 
composition of Stat3ǻM CRCs is most likely due to an altered cytokine and chemokine milieu 
that leads to differential attraction of immune cells. Consistent with this hypothesis, 
expression of stem cell factor (SCF), which is the major chemoattractant for mast cells, was 
found downregulated in tumor and stroma compartments of Stat3ǻM CRCs (data not shown). 
This explains the reduced number of mast cells which was also reflected by reduced 
expression of mast cell proteases mcpt1 and mcpt2 in the stroma of Stat3ǻM CRCs (data not 
shown). Interestingly, reduced numbers of stromal mast cells and increased numbers of 
stromal T cells favored prognosis of human CRCs patients33. This indicates a reciprocal 
correlation between stromal T cell activation and reduced mast cell numbers which was also 
observed in the stroma of Stat3ǻM CRCs. Higher vessel density was an additional stromal 
change in Stat3ǻM CRCs although they contained M1 polarized macrophages which don’t 
support angiogenesis as efficient as M2 polarized macrophages. Moreover, it has been 
demonstrated that STAT3 activation in MDSCs and TAMs of transplanted B16 melanomas 
favors tumor angiogenesis via regulation of several pro- and anti-angiogenic factors including 
VEGF, bFGF, IL1ß, MMP9, CCL2 and CXCL246. This controversy might be reconciled by 
WGCN analysis of the tumor stroma which did not reveal single factors that could explain 
increased vessel density in Stat3ǻM CRCs. However, negative regulators of angiogenesis 
were predominantly downregulated and positive regulators were predominantly upregulated 
indicating that the altered cytokine milieu and distinct cellular immune cell composition in 
Stat3ǻM CRCs might favor angiogenesis via pleiotropic effects.  
According to the concept of immunoediting, transformed cells are initially eradicated by NK, 
NKT and T cell responses. Surviving cancer cells remain in equilibrium between tumor cell 
proliferation and eradication by T cell activities. Edited tumor cell, however, escape T cell 
attack through various mechanisms and establish primary growths47. It has been 
demonstrated that tumors in immune compromised mice are less edited and express tumor 
antigens that would lead to eradication in immune competent hosts. This experimental 
system has mainly been used to identify tumor antigens implicated in immune editing47. In 
contrast to immune compromised mice, CRCs in Stat3ǻM mice face a strong immunogenic 
environment. The CRCs were unable to reshape their stroma towards a tumor-promoting 
immune cell composition by tumor derived factors. The sustained stromal immune activities 
might force Stat3ǻM CRCs to develop tumor cell-autonomous strategies for immune escape 
apart from mere downregulation of tumor antigens. Therefore, we interpret the changes of 
STAT3, NFțB, Myc and SMAD signaling pathways in Stat3ǻM CRCs as editing events 
essential for tumor cell survival. Among these pathways, the importance for STAT3 
expression in tumor cells and its relevance for immune evasion is well documented48, 49 and 
has been demonstrated for various cancers including glioblastoma50, 51 and squamous cell 
carcinoma52. Activation of STAT3 in tumor cells inhibits expression of Th1 immune 
stimulatory molecules. In contrast, activation of NFțB induces expression of Th1 mediators53. 
Therefore, p65-expressing Stat3ǻM CRCs might be counter selected, despite the tumor-
promoting activity of NFțB, because of further augmentation of anti-tumor immune 
responses. Interestingly, many of the Th1 mediators induced by NFțB are repressed by 
STAT353. Consequently, activation of STAT3 and simultaneous repression of NFțB in 
Stat3ǻM CRCs could lead to escape of tumors that are immunologically inconspicuous 
because of their compromised cytokine secretory phenotypes.  
STAT3 inhibitors are in clinical trials for various types of leukemias and solid cancers54. Our 
data suggest that inhibition of STAT3 in CRCs would interfere with immune evasion of tumor 
cells and simultaneously increase anti-tumor T cell activities in the stroma. Combinatorial 
therapies with STAT3 inhibitors and inhibitors for immune evasion pathways could have 
similar synergistic effect for prevention of tumor relapse after immunotherapy.  
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Methods 
 
Mice and in vivo experiments 
C57BL/6 STAT3¨M (= LysMCre/Cre STAT3flox/flox) and corresponding STAT3wt control (= 
LysMCre/Cre STAT3+/+) mice55, 56 were employed for tumor induction with AOM/DSS. The 
LysMCre knock-in alleles were kept homozygous to account for potential Cre or LysM knock-
in effects. For tumor transplantation studies, 1x105 of p185 or 1x106 of MC38 cells were 
injected subcutaneously. Host mice were sacrificed and tumors were weighed and analysed 
by flow cytometry 11 days (p185) and 14 days (MC38) after tumor transplantation.  
In vivo cytotoxicity was evaluated as described57. In brief, mice were immunized by 
subcutaneous injection of 0.1mg/mouse m-TRP2181-188 (Bachem) in combination with the 
adjuvant CpG-ODN 1668. Seven days later control mice and immunized mice received 
syngeneic splenocytes labeled with three different concentrations of the intracellular dye 
carboxyfluorescein succinimidyl ester (CFSE): 2.5, 0.25 and 0.025µM. The CFSEhigh 
population was pulsed with the relevant m-TRP2181-188 (10µg/ml), the CFSEmid population was 
pulsed with the irrelevant peptide m-SIINFEKL (Bachem; 10µg/ml) and the CFSElow 
population remained untreated. All three differently pulsed CFSE+ populations were mixed in 
a 1:1:1 ratio and approximately 3x107 cells were injected via the lateral tail veins of recipient 
STAT3wt and STAT3¨M animals. 18 hours thereafter draining lymph nodes were removed. 
Single cell suspensions were analyzed by flow cytometry and specific killing was calculated 
as >1-(% CFSEhigh / % CFSElow)@ x 100.  
In order to obtain peritoneal macrophages, STAT3wt and STAT3ǻM mice were i.p. injected 
with 4% thioglycerol (Sigma) and sacrificed after 4h. Peritoneal macrophages were isolated 
by FACS analysis using antibodies against F4/80.  
All mouse experiments were performed in accordance with Austrian and European laws and 
with the general regulations specified by the Good Science Practices guidelines of the 
Medical University of Vienna. 
 
In vitro cytotoxicity assay of NK cells 
STAT3wt and STAT3¨M mice were injected i.p. with PBS or 100µg poly(I:C) in order to 
activate NK cells and spleen cells were isolated after 18 hours. Splenocytes were incubated 
with 5x104 CFSE-stained (2.5µM) YAC-1 target cells at effector-to-target ratios of 100:1, 50:1 
and 25:1 in triplicates in 96-well plates. To assess the extent of spontaneously occurring 
apoptosis, tumor cells were incubated in the absence of NK cells. After 6h 7-AAD Viability 
Solution was added and cytotoxicity was quantified by flow cytometry. Cytotoxicity was 
normalized to quantified NK numbers of splenic single cell suspensions.  
 
 Differentiation of monocytes from primary bone marrow cells 
Monocytes were differentiated from bone marrow of STAT3wt and STAT3ǻM mice using 
DMEM (Sigma-Aldrich) supplemented with Penicillin/Streptomycin (PAA), Glutamin (PAA), 
10% FCS (PAA), and 10% supernatant from L-929 cells. Bone marrow cells were 
differentiated for 10 days and medium was changed every 2-3 days. Differentiation into 
monocytes was confirmed using flow cytometry.  
 
Isolation of lamina propria lymphocytes 
Lamina propria lymphocytes were isolated as described51. Colons of 3 mice per genotype 
were flushed with PBS and opened longitudinally. Tissue pieces of 3-4mm were shaken in 
Hank’s balanced salt solution containing 5mM EDTA and 10mM Hepes at 37°C for 2x15min 
to separate the lamina propria lymphocytes from the epithelial layer. Then, tissue pieces 
were shaken in Hank’s balanced salt solution containing FCS, Dispase [1U/ml], Collagenase 
[25U/ml] and DNAse [30U/ml] at 37°C for 3x20min. The supernatant was centrifuged and 
subjected to Percoll gradient centrifugation. The lymphocytes at the interface between the 
40% and the 80% layers were collected, washed in ice cold PBS and then used for flow 
cytometry.  
 
Histology and immunohistochemistry (IHC) 
Whole intestines were flushed with PBS and 4% buffered formaldehyde and fixed as Swiss 
roles in 4% formaldehyde. 4µm paraffin sections representing the whole intestine were 
stained with H&E, alcian blue, neutrophilic esterase, toluidin blue or IHC using standard 
procedures. IHC stainings were performed with antibodies for Tyr-705 phosphorylated 
STAT3 (Cell signaling), STAT3 (Santa Cruz), Tyr-701-phoshorylated STAT1 (Cell signaling), 
STAT1 (Santa Cruz), Ki67 (Novocastra), cleaved caspase 3 (Cell signaling), ß-Catenin (BD 
Transduction Laboratories), Lysozyme (Dako), Synaptophysin (Genetex), van Willebrand 
Factor (DAKO), Fsp1 (Millipore), PDGFR (cell signaling), CD3 (Neomarkers), F4/80 (AbD 
Serotec), GranzymeB (Abcam), CD8a (Biolegend), FoxP3 (Santa Cruz), RORgT (Biolegend), 
CD11c (Biolegend), NKp46 (Biolegend), NKG2D (Santa Cruz), NKG2A (Biolegend), Gr1 
(Serotec), Arg1 (Santa Cruz), iNOS (Biolegend), TGFß (Santa Cruz), P-SMAD2 (Chemicon), 
Smad7 (Santa Cruz), and detected them with peroxidase-coupled secondary antibody (ID 
labs) using AEC chromogen (ID labs).  
 
Flow cytometric analysis 
Spleens from STAT3wt and STAT3¨M animals were squeezed through a 70µm cell strainer 
and red blood cells were removed using Red blood cell Lysis Buffer (Sigma) according to 
manufacturer´s instruction. Splenocytes were analyzed with the following antibodies: aCD3e-
Pacific Blue, aCD49b-APC-Cy7, aNK1.1-PE-Cy7, aNKp46-APC, aCD27-PE, aCD11b-
PerCP-Cy5.5, aNKp46-PE, aKLRG1-FITC, aCD226-APC, Ly49A/D purified, a-Rat IgG-FITC, 
aLy49C/I-Biotin, Streptavidin-PerCP-Cy5.5, aNKG2D-APC, aNKG2A/C/E-FITC and 
aCD16/CD32 as Fc receptor block (all eBioscience). The Cell Trace CFSE Cell Proliferation 
Kit (Invitrogen) and the 7-AAD Viability Solution (eBioscience) was used according to the 
manufacturer’s instruction. Samples were analyzed using a FACSCantoTM II flow cytometer 
(BD Biosciences) and data were calculated with FACSDiva software (BD Biosciences).  
For staining of macrophages, splenic immune cells and lamina propria lymphocytes, cells 
were preincubated with PBS containing 0.5% BSA and FCȖIII/IIR antibody to block 
nonspecific binding. Cells were stained with following antibodies:  aCD3-Percp, aCD4-PE, 
aCD8-APC, aCD25-APC, aGr1-PE, aCD11c-Brilliant Violett, aCD11b-Alexa Fluor 488, 
aNKG2D-APC, aCD49b-PE/cy7, aCD45/B220-Alexa Fluor 488, aI-A/I-E-PerCP, aCD80-
Pacific Blue, aLy49D-Fitc, aCD69-Fitc, aCD19-PE/Cy7, aCD45-Pacific Blue (all Biolegend), 
aFoxP3, aRORgT, aF4/80-APC, aNKp46-FITC,  aNK1.1-PE (all eBioscience). Data were 
collected on a FACS Fortesssa (Beckton Dickinson) and analyzed with FACSdiva software 
software (BD Biosciences). Fluorescent cell sorting of splenocytes was performed on a 
BDFACS Aria (Beckton Dickinson).  
 
Western blot 
Protein extracts from whole colon, sorted peritoneal macrophages and in vitro differentiated 
macrophages were analyzed by Western blot using antibodies against total STAT3 (Cell 
Signaling).  
 
Quantitation and staging of tumors 
TissueFaxs software (TissueGnostics GmbH) was used to scan H&E-stained swiss roles. 
Quantitation of tumor area and IHC stainings was performed using HistoQuest software 
(TissueGnostics GmbH) or ImageJ. Tumor grading was performed by a board-certified 
pathologist.  
 
Polymerase Chain Reaction (PCR) Analysis 
Genotyping of STAT3 was performed with primers 5’-CACCAACACATGCTATTTGTAGG-3’, 
5’-GCAGCAGAATACTCTACAGCT-3’ and 5’-GCAGCAGAATACTCTACAGCTC-3’. The Cre 
transgene was detected with primers 5’-CGGTCGATGCAACGAGTGATGAGG-3’ and 5’-
CCAGAGACGGAAATCCATCGCTCG-3’. Real-time PCR was performed with an ABI cycler 
(Applied Biosystems). Relative expression levels of transcripts were calculated using the 
comparative CT method and normalized for GAPDH. Primer sequences are available upon 
request.  
 
Laser Capture Microdissection (LCM) 
5µm paraffin sections of the intestine were placed on PEN Membrane glass slides 
(Alphametrix Biotech). 8 slides per mouse were used for LCM using an Arcturus Alphametrix 
System and tumor samples were collected in Capsure Macro LCM Caps (Alphametrix 
Biotech). Total RNA from tumor and stroma tissue was isolated using the RNeasy FFPE kit 
(Qiagen) according to the manufacturer's protocol (each RNA sample represented a pool of 2 
tumors isolated from one mouse; n=3 mice per genotype).  
 
Microarray analysis 
RNA from paraffin material was labeled and hybridized to mouse whole genome GeneChip 
Mouse Gene 2.0ST arrays (Affymetrix) according to manufacturer's instructions. Microarray 
data were analyzed using Limma package of R with the parameters “mouse”, “tissue type” 
(tumor and stroma) and “genotype” using a paired approach with “mouse” as pairing 
variable58. P values were adjusted according to Benjamini-Hochberg59. An adjusted P value < 
0.05 was considered as significant.  
 
Weighted Gene Co-expression Network Analysis (WGCNA) 
The Pearson correlations were calculated for all pairs of genes in the samples. The resulting 
correlation matrix was transformed into a matrix of connection strengths by raising the 
absolute value of the correlation coefficients to the power ȕ. A ȕ of 6 was used to satisfy the 
scale free topology criterion54. The top 25% of genes displaying the highest variability over 
the entire dataset were selected for module detection. From these genes, modules were 
determined using the “blockweise” module detection function of the WGCNA package with 
default values except for the minimal module size and the merge cut height parameters (set 
to 20 and 0.05 respectively). Biological functions of the single modules were determined 
using the GO term enrichment analysis function of WGCNA. Only “biological 
function“ ontology was included into the analysis55-57.  P values of enriched terms were 
adjusted as above according to Benjamini-Hochberg. An adjusted P value < 0.05 was 
considered as significant.  
 
Statistics 
Significant differences in tumor parameters, IHC stainings and RT-PCR data were calculated 
with GraphPad Prism 5 software using unpaired t test and Mann-Whitney post test. Multiple 
comparisons were calculated with One-way Anova and Bonferroni post-test. Significant 
differences between experimental groups were: *P < 0.05, **P < 0.01, or ***P < 0.005. 
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Figure 1. Myeloid STAT3 promotes formation of colorectal tumors. (a) 
After application of the AOM/DSS protocol (scheme), (b) Decreased 
colon tumor number and mean tumor size in male (n=13 for control and 
n=16 for STAT3'm mice) and female (n=6 for control and n=8 for 
STAT3'm mice) STAT3'm mice. (c) Loss of STAT3 in myeloid cells had 
no impact on tumor cell proliferation and survival but results in (d) 
increased angiogenesis. Blood vessels are indicated by arrowheads. 
Scale bar indicates 50m. The bar diagrams were obtained by quantita-
tion of Ki67-positive nuclei, caspase-3-positive apoptotic cells and 
vWF-positive blood vessels on IHC-stained section of tumors.
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Figure 2. Loss of myeloid Stat3 changes stromal area and stromal 
composition of tumors. (a) Increased stromal area in Stat3wt tumors: 
H&E staining (upper panel, scale bar indicates 100m); Fsp1/PDGFR 
IHC staining (lower panel, scale bar indicates 50m) reveals increased 
stromal area in Stat3ǻm tumors. (b) IHC staining of stromal cells reveals 
similar percentage of macrophages (F4/80), reduced percentage of 
granulocytes (neutrophile esterase), regulatory T cells (RORgT), and 
Mast cells. Corresponding cell types are indicated by arrowheads. Scale 
bar indicates 50m. (c) Stat3'm tumors display reduced percentage of 
Arginase1+ cells, and increased percentage of CD163+ and iNOS+ cells. 
IHC stainings were analysed in n9 tumors per mouse. (d) Histopatholo-
gical grading of colon tumors in male and female mice revealed no 
significant change in Stat3'm mice (calculation: number of carcinomas 
per mouse/total tumor number per mouse x100). 97 tumors identified in 
Stat3wt mice and 26 tumors identified in Stat3'm mice were analysed. 
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Figure 3. In vitro NK cytotoxicity assay and characterization of NK cells 
from spleens of Stat3'm and control mice. (a) flow cytometric analysis of 
specific lysis of CFSE-labeled YAC-1 target cells in different 
effector:target ratios by splenocytes from Stat3'm and control mice, 
injected with phosphate buffered saline or Poly(I:C) (n=3 per group). (b) 
Flow cytometric analysis of Stat3'm and control splenocytes demonstra-
ting reduced percentage of CD3- NKp46+ Ly49D+ cells (n4). (c) tumor 
weight of transplanted p185 tumor cells into Stat3'm and control mice 
(n=15 tumors in control and n=11 tumors in Stat3'm mice). (d) Loss of 
NK cells does not affect tumor initiation and tumor growth in long term 
AOM/DSS treated Stat5'NK mice. (e) Analysis of tumor multiplicity 
(tumors/cm2 gut) and tumor size (mean tumor area) revealed similar 
tumor numbers and tumor size upon loss of NK cells (n=11 for Stat5'NK 
mice and n=8 for Stat5fl/fl); flow cytometric analysis reveals reduced 
colon NK (CD45+ CD3-  CD19- NKp46+) cells.
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Figure 4. Characterization of cytotoxic T lymphocytes in Stat3ǻm mice. 
(a) In vivo cytotoxicity assay of Stat3ǻm and control mice immunized with 
0.1mg/mouse m-TRP2181-188 in combination with the adjuvant CpG-ODN 
1668. Specific killing ([1-(% CFSEhigh / % CFSElow)] x 100) was calcula-
ted of CFSE-labeled target cells analysed via flow cytometry (n=x per 
group). (b) tumor weight of transplanted MC38 tumor cells into Stat3ǻm 
and control mice (n=12 tumors in control and n=14 tumors in Stat3ǻm 
mice); flow cytometric analysis of MC38 tumors reveals increased 
numbers of NKG2D+ cells, increased percentage of T cells, MDSCs 
(Gr1hi CD11b+ cells) and TAMs (Gr1lo CD11b+ CD11clo) cells.
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Figure 5. Weighted Gene Co-expression Network Analysis of microarray 
data obtained from RNA of laser-capture-microdissected colorectal 
tumors from Stat3ǻm and control tumors. Gene expression was compa-
red between Stat3ǻm stroma and Stat3wt stroma. Modules of highly 
correlated genes were identified for (a) Immune response genes, and (b) 
Inflammatory response genes. Blue node color represents downregulati-
on, red node color represents upregulation of gene expression in the 
stroma of Stat3ǻm tumors. Node size is associated with the gene’s 
co-expression in the entire dataset; edge (line) thickness is linked to the 
gene’s connectivity (co-expression within the module).
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Figure 6. Immunohistochemistry stainings of colon tumors in long term 
AOM/DSS treated Stat3wt and Stat3ǻm mice (n9 tumors per genotype). 
(a) IHC staining for total Stat3 and Tyr-705-phosphorylated Stat3 
(P-Stat3) revealed higher levels in Stat3ǻm tumors compared to Stat3wt. 
(b) c-Myc IHC staining demonstrated increased expression in Stat3ǻm 
tumors. (c) IHC staining for NFkB p65 revealed reduced number of 
positive tumor cells in Stat3ǻm tumors. (d) P-Samd2 IHC demonstrated 
increased numbers of positive cells in Stat3ǻm tumors. (e) IHC staining 
for TGFErevealed higher levels of positive cells in the stroma but not 
tumor cells of Stat3ǻm tumors; IHC stainings were analysed in n9 
tumors per genotype. Real-time polymerase chain reaction analysis 
demonstrates similar tgfE levels in bone marrow – derived macrophages 
of Stat3wt and Stat3'm mice (bars represent data +/- standard error of 
mean from 3 animals per genotype). Scale bar indicates 50m. 
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Supplementary Figure 1. Confirmation of Stat3 ablation in myeloid 
cells. (a) Western blot analysis for total Stat3 demonstrating loss of Stat3 
protein in tissue from total colon (n=3 mice per genotype), granulocy-
te-monocyte progenitors derived from bone marrow (FACS blot, n=3 
mice per genotype) and peritoneal macrophages (n=3 mice per genoty-
pe) in Stat3'm mice. GAPDH was used as loading control. (b) Real-time 
polymerase chain reaction analysis of Stat3 in macrophages FACS-sor-
ted from splenocytes of Stat3wt and Stat3'm mice. Bars represent data +- 
standard error of mean from 6 animals per genotype. 
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Supplementary Figure 2. Characterization of mice with a conditional 
ablation of Stat3 in myeloid cells. (a) Quantitation of paneth cells, entero-
endocrine cells and goblet cells in the colon of Stat3ǻm mice. The bars 
represent average numbers of positively stained cells +- standard error 
of mean in 9 crypts or villi (n=3 mice per genotype). Immunohistoche-
mistry for Lysozyme and Synaptophysin, and Alcian blue-staining 
demonstrated the presence of paneth cells, enteroendocrine cells, and 
goblet cells in the colon of Stat3ǻm mice.  Ki67-staining revealed prolife-
rating cells in the crypts of Stat3ǻm mice. Corresponding cell types are 
indicated by arrowheads. (b) H&E staining and Immunohistochemistry 
staining for F4/80 and CD3 of colons from untreated Stat3ǻm and control 
mice. Scale bar indicates 100m.  
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Supplementary Figure 3. Flow cytometric analysis of splenic cells and 
lamina propria immune cells after short term DSS treatment in Stat3wt 
and Stat3'm mice. (a) splenic immune cells, (b) similar levels of CD3+ 
CD4+ cell activation; (c) lamina propria immune cells, (d) increased 
CD3+ CD4+ cell activation. 
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Supplementary Figure 4: Charakterization of stromal composition of Stat3wt and Stat3'm tumors. Immunohistochemistry stainings for (a) granulocytes 
(Gr1), (b) dendritic cells (CD11c), (c) T cells (CD3) , (d) cytotoxic T cells (CD8), (e) Plasma cells (CD138), (f) regulatory T cells (FoxP3), (g) B cells 
CD45R, (h) NK cells (NKp46) of Stat3wt and Stat3'm colon tumors; n9 tumors per genotype. Corresponding cell types are indicated by arrowheads. 
Scale bar indicates 50m. 
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Supplementary Figure 5. Flow cytometric analysis of splenic NK cells. 
(a) Similar expression of Dx5 and maturation markers (CD27, KLRG-1) 
in Stat3ǻm and control mice (n=3 mice per group). (b) Similar expression 
of NKG2D, NKG2A and Ly49C/I in Stat3ǻm and control mice (n4).
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Supplementary Figure 6. The Cytoscape plots and significantly enriched GO terms. The four most enriched terms or signaling pathways in knockout vs 
wildtype modules are shown representing the top 150 protein connections in each color module as calculated by adjacency between genes. Node size 
represents connectivity and the nodes in the middle of each Cytoscape plot are the “hub genes” for each module. 
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Supplementary Figure 7. WGCA of microarray data from 
laser-capture-microdissected colorectal tumors, comparing Stat3ǻm 
stroma and Stat3wt stroma for the module “angiogenesis”.
Supplementary Figure 8. E-Catenin levels are similar between Stat3wt 
tumors and Stat3ǻm tumors. Scale bar indicates 50m. 
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Supplementary Figure 9. RNA expression data of laser-capture 
microdissected tumor and stroma tissue from Stat3ǻm and control mice. 
(a) ICR (Immunologic Constant of Rejection) genes (b) T cell activity (left 
panel), IL-2 receptors (right panel), (c) tumor-derived factors(left panel),  
(d) stress-induced NKG2D ligands (e) mCRPs. 
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